Prostate Cancer - Results from #22920

Slide Lecture: Immunotherapy and vaccines in castration resistant prostate cancer: What do we know so far and clinical applications June 14, 2013

Classifying the reasons men consider to be important in prostate-specific antigen (PSA) testing decisions: Evaluating risks, lay beliefs, and informed decisions - Abstract June 14, 2013

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy - Abstract June 14, 2013

Phase I pharmacokinetic and biodistribution study with escalating doses of (223)Ra-dichloride in men with castration-resistant metastatic prostate cancer - Abstract June 14, 2013

Plan of the day selection for online image-guided adaptive post-prostatectomy radiotherapy - Abstract June 13, 2013

Current role of surgery for high risk prostate cancer - Abstract June 13, 2013

Cost-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer - Abstract June 13, 2013

Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract June 13, 2013

Functional and molecular imaging of localized and recurrent prostate cancer - Abstract June 13, 2013

PSA screening and deaths from prostate cancer after diagnosis-A population based analysis - Abstract June 13, 2013

Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening - Abstract June 13, 2013

Unmet needs in the prediction and detection of metastases in prostate cancer - Abstract June 13, 2013

Statement by NIH Director Francis Collins on U.S. Supreme Court ruling on gene patenting June 13, 2013

Breaking News: Can someone else patent your genes? No, according to a closely watched ruling from the U.S. Supreme Court Thursday morning June 13, 2013

ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: P June 13, 2013

ASCO 2013 - Poster: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial June 13, 2013

ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer June 13, 2013

ASCO 2013 - Poster: Randomized double-blind, comparative study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) vs ADT alone in newly diagnosed, high-risk, metastatic hormone-naïve prostate cancer June 13, 2013

ASCO 2013 - Poster: Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer June 13, 2013

ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA) June 12, 2013

Page 1147 of 1434